Iterum Therapeutics plc (ITRM) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Dublin, アイルランド. 現CEOは Corey N. Fishman.
ITRM を有する IPO日 2018-05-25, 9 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $1.6M.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
